Pharmacies are struggling to keep shelves stocked with at-home COVID-19 tests during the current Omicron surge. Abbott, maker of BinaxNOW, said it is ramping up production to match “unprecedented demand.” (CNBC Weekly)
In a new update, the Centers for Disease Control and Prevention stuck to its COVID-19 isolation guidance. The updated guidelines involve a five-day isolation period and wearing a mask for an additional five days, but don’t require testing during the isolation period. (CNN)
In the wake of their COVID vaccine triumph, Pfizer and BioNTech are planning to develop an mRNA vaccine for shingles. Clinical trials will likely start in the second half of 2022. (Reuters)
Scientists are turning their focus to CRISPR therapeutics as the pharma industry enters the third year of the pandemic. Many scientists believe that CRISPR innovations like community editing, epigenome editing and RNA editing will expand in 2022. (STAT)
Catalent CEO John Chiminski will step down after 12 years to become executive chair of the company’s board. Alessandro Maselli, currently the company’s president and COO, will assume the CEO role in July. (Endpoints News)
